GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revance Therapeutics Inc (STU:RTI) » Definitions » Cash From Discontinued Investing Activities

Revance Therapeutics (STU:RTI) Cash From Discontinued Investing Activities : €0.0 Mil (TTM As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Revance Therapeutics Cash From Discontinued Investing Activities?

Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Revance Therapeutics's cash from discontinued investing activities for the three months ended in Sep. 2024 was €0.0 Mil. It means Revance Therapeutics received €0.0 Mil from discontinued investing activities. Revance Therapeutics's cash from discontinued investing activities for the trailing twelve months (TTM) ended in Sep. 2024 was €0.0 Mil.

Revance Therapeutics Cash From Discontinued Investing Activities Historical Data

The historical data trend for Revance Therapeutics's Cash From Discontinued Investing Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revance Therapeutics Cash From Discontinued Investing Activities Chart

Revance Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash From Discontinued Investing Activities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Revance Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash From Discontinued Investing Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Revance Therapeutics Cash From Discontinued Investing Activities Calculation

Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Cash From Discontinued Investing Activities for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revance Therapeutics Cash From Discontinued Investing Activities Related Terms

Thank you for viewing the detailed overview of Revance Therapeutics's Cash From Discontinued Investing Activities provided by GuruFocus.com. Please click on the following links to see related term pages.

Revance Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revance Therapeutics Inc (STU:RTI) » Definitions » Cash From Discontinued Investing Activities
Comparable Companies
SLNCF ABSI ATYR VYGR SLRN ENGN CMRX XOMA JSPR CRVS VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
RVNC:USA
Address
1222 Demonbreun Street, Suite 2000, Nashville, TN, USA, 37203
Website
https://www.revance.com
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

Revance Therapeutics Headlines

No Headlines